secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xilio Therapeutics, Inc. (XLO)
CIK:        0001840233
Form:       8-K
Filed at:   2022-07-28T23:59:59+00:00
Accession:  0001558370-22-011295
Event type: leadership
Sentiment:  negative
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Xilio Therapeutics CFO Salvatore Giovine resigns effective Aug 19, 2022
-----------------------------------------------------------------------

- CFO Salvatore Giovine resigned for personal family reasons, effective August 19, 2022.
- No successor or interim CFO was announced in this filing.
- Giovine served as principal financial officer of the company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840233/000155837022011295/0001558370-22-011295-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840233/000155837022011295/xlo-20220725x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-011295

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer